Investing.comDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 19:04:33·⟳ 抓取 19:05:17 +44s·⚡ 决策 10-12 19:08:00 +2m43s·15.3 天前
First Tracks Biotherapeutics（TRAX.US）ANB033 乳糜泻 Phase 1b 第一队列达到主要组织学终点，盘前暴涨约52%
临床结果方向明确且为公司核心资产的真实去风险事件，但盘前在极薄成交下已跳涨约52%（31.85→48.41美元，盘前高见49.00），实质重定价在开盘前已完成大半；Phase 1b 仅32人、后续 Cohort 2 要等2027Q1、后期试验2027年才启动，无收入小盘 biotech 在+52%位置追入的回撤风险显著高于剩余 edge，且盘前5.5万股的流动性无法支持右侧确认。
📄 原文Investing.com↗ 原文
First Tracks’ ANB033 meets celiac disease trial endpoints
By Investing.com Advertisement Advertisement First Tracks’ ANB033 meets celiac disease trial endpoints Company News Pub…
不做 First Tracks Biotherapeutics（TRAX.US）
真实阳性催化但盘前数分钟内已在极薄成交下跳涨约52%（31.85→48.41，接近52周高位49.91），早期Phase 1b、下一实质催化在2027Q1，开盘冲高回落风险大、剩余edge不覆盖回撤风险；不在盘前/开盘追高，若开盘后放量站稳并回踩不破可另作右侧评估
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ANB033 乳糜泻 Phase 1b Cohort 1 组织学与症状双阳性、安全性干净并具 Fast Track，属实质利好；但 TRAX 盘前已暴涨约52%且成交极薄，早期数据+远期催化下追高风险收益比不足，不做。
消息传播链
- 07:04 ET 发布 ANB033 Phase 1b Cohort 1 阳性结果；该文为 AI 辅助改写的新闻稿报道，未直接取得公司IR原文链接，但数据细节（p值、样本量、用药比例）完整一致市场反应:盘前 TRAX 由31.85美元升至48.41美元（+52%），盘前高49.00、低35.45，成交约5.6万股
关键理由
- 核心资产 ANB033 首次在随机对照面筋挑战模型中同时拿到组织学（p=0.009、p<0.001）与症状终点阳性，显著降低机制风险并支撑2027年后期试验
- 公司为2026年4月由 AnaptysBio 分拆的单资产型小盘 biotech（事件前市值约11.4亿美元），数据对单一资产公司的边际影响极大，这也是盘前+52%重定价的原因
主要风险
- 32例 Phase 1b 小样本、6周短疗程，组织学终点临床意义与 Cohort 2（2027Q1）可复制性仍待验证，biotech 数据盘常见开盘冲高回落
- 盘前仅约5.6万股成交、买卖价差较大，若开盘流动性兑现不足，+52%跳空可能大幅回吐
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-12 · 影响 weakens
未发现安全性信号或数据造假/否认类反证，但32人小样本、短疗程、Cohort 2未读出构成固有弱点；无正式利空，仅有早期数据不确定性
检索:ANB033 celiac phase 1b criticism limitations cohort 2 safety placebo 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加盘前已重定价约52%，直接支持不追高、AVOID 的结论
方向:本轮未取得锚点干净的同市场同类先例：检索仅返回 Forte/argenx 乳糜泻项目 Fast Track 与其他 biotech 单日异动报道，无法在不编造首发锚点的情况下用于校准幅度
涨幅量级:无可信 aligned 先例；实际盘前+52%的瞬时重定价是当前唯一幅度参照，且该跳空本身已构成追高障碍
形态:早期临床阳性数据的小盘 biotech 常见开盘冲高后部分回吐，但无干净样本支撑量化结论，仅作为降仓/不追的定性背景
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`first tracks anb033 cohort 1 gluten challenge fast track | first tracks biotherapeutics anb033 celiac disease phase 1b results | trax anb033 cd122 antagonist villus height crypt de`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{ - stock_quote 成功 stock_tools HTTP · 1,192 ms
{ - web_search 成功 doubao_search · 2,650 ms
豆包搜索结果（原始查询:First Tracks Biotherapeutics TRAX ANB033 celiac Phase 1b positive results press release；API SearchType:web） - web_search 成功 doubao_search · 3,071 ms
豆包搜索结果（原始查询:small biotech phase 1b positive celiac disease data stock reaction premarket gap fade 2026 TRAX First Tracks；API SearchType:web）
原文全文
展开原文 · 7,383 字
First Tracks’ ANB033 meets celiac disease trial endpoints By Investing.com
Advertisement
Advertisement
First Tracks’ ANB033 meets celiac disease trial endpoints
Company News
Published
Oct 12, 2026, 07:04 AM
First Tracks’ ANB033 meets celiac disease trial endpoints
View all comments (0)
0
First Tracks’ ANB033 meets celiac disease trial endpoints
View all comments (0)
0
© Reuters
In this article:
TRAX
-0.50%
SAN DIEGO -
First Tracks Biotherapeutics
Inc. (
NASDAQ:TRAX
) reported positive results from Cohort 1 of its Phase 1b trial for ANB033 in celiac disease, according to a press release statement issued today.
The randomized, placebo-controlled trial evaluated 32 patients who received either ANB033 or placebo over six weeks, followed by a 14-day gluten challenge equivalent to two slices of bread daily. The study assessed ANB033, a subcutaneously administered CD122 antagonist designed to inhibit IL-15 and IL-2 signaling on immune cells.
ANB033 demonstrated statistically significant differences compared to placebo across key histologic endpoints. The least squares mean change from baseline in villus height-to-crypt depth ratio was -0.17 on ANB033 versus -0.66 on placebo, representing a placebo-adjusted delta of +0.49 (p=0.009). Intraepithelial lymphocyte density showed a least squares mean change of -1.20 on ANB033 versus +18.83 on placebo, a placebo-adjusted delta of -20.03 (p<0.001).
The trial also measured symptoms using the Celiac Disease Symptom Diary throughout the gluten challenge. ANB033 showed lower symptom scores compared to placebo, with statistical significance from the first day through the seventh day. Additionally, 47% of placebo patients took permitted medications for gastrointestinal symptoms compared to 6% of ANB033 patients.
The safety profile showed no serious adverse events, no severe adverse events, and no adverse events leading to discontinuation in the ANB033 group. Common adverse events occurring in three or more participants included injection site erythema, nausea, and abdominal pain.
First Tracks plans to initiate a late-stage clinical trial in celiac disease in 2027. The FDA has granted ANB033 Fast Track designation. Cohort 2 results are expected in the first quarter of 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
First Tracks’ ANB033 meets celiac disease trial endpoints
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,694.50
+39.3
+0.08%
US 500
7,814.00
+2.5
+0.03%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.50
+0.66
+4.45%
Dollar Index
102.21
+0.188
+0.18%
Crude Oil WTI Futures
92.92
+1.07
+1.16%
Brent Oil Futures
105.97
+1.25
+1.19%
Natural Gas Futures
3.145
-0.075
-2.33%
Gold Futures
4,199.25
-17.05
-0.40%
Silver Futures
60.898
-0.151
-0.25%
Copper Futures
6.7668
+0.0748
+1.12%
US Soybeans Futures
1,282.88
-8.13
-0.63%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.53
-0.06
-0.06%
Euro Bund Futures
121.05
-0.03
-0.03%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Premarket movers: Iren jumps on Anthropic deal, CCC surges on buyout talks
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
First Tracks’ ANB033 meets celiac disease trial endpoints
Company News
Published
Oct 12, 2026, 07:04 AM
First Tracks’ ANB033 meets celiac disease trial endpoints
View all comments (0)
0
First Tracks’ ANB033 meets celiac disease trial endpoints
View all comments (0)
0
© Reuters
In this article:
TRAX
-0.50%
SAN DIEGO -
First Tracks Biotherapeutics
Inc. (
NASDAQ:TRAX
) reported positive results from Cohort 1 of its Phase 1b trial for ANB033 in celiac disease, according to a press release statement issued today.
The randomized, placebo-controlled trial evaluated 32 patients who received either ANB033 or placebo over six weeks, followed by a 14-day gluten challenge equivalent to two slices of bread daily. The study assessed ANB033, a subcutaneously administered CD122 antagonist designed to inhibit IL-15 and IL-2 signaling on immune cells.
ANB033 demonstrated statistically significant differences compared to placebo across key histologic endpoints. The least squares mean change from baseline in villus height-to-crypt depth ratio was -0.17 on ANB033 versus -0.66 on placebo, representing a placebo-adjusted delta of +0.49 (p=0.009). Intraepithelial lymphocyte density showed a least squares mean change of -1.20 on ANB033 versus +18.83 on placebo, a placebo-adjusted delta of -20.03 (p<0.001).
The trial also measured symptoms using the Celiac Disease Symptom Diary throughout the gluten challenge. ANB033 showed lower symptom scores compared to placebo, with statistical significance from the first day through the seventh day. Additionally, 47% of placebo patients took permitted medications for gastrointestinal symptoms compared to 6% of ANB033 patients.
The safety profile showed no serious adverse events, no severe adverse events, and no adverse events leading to discontinuation in the ANB033 group. Common adverse events occurring in three or more participants included injection site erythema, nausea, and abdominal pain.
First Tracks plans to initiate a late-stage clinical trial in celiac disease in 2027. The FDA has granted ANB033 Fast Track designation. Cohort 2 results are expected in the first quarter of 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
First Tracks’ ANB033 meets celiac disease trial endpoints
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,694.50
+39.3
+0.08%
US 500
7,814.00
+2.5
+0.03%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.50
+0.66
+4.45%
Dollar Index
102.21
+0.188
+0.18%
Crude Oil WTI Futures
92.92
+1.07
+1.16%
Brent Oil Futures
105.97
+1.25
+1.19%
Natural Gas Futures
3.145
-0.075
-2.33%
Gold Futures
4,199.25
-17.05
-0.40%
Silver Futures
60.898
-0.151
-0.25%
Copper Futures
6.7668
+0.0748
+1.12%
US Soybeans Futures
1,282.88
-8.13
-0.63%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.53
-0.06
-0.06%
Euro Bund Futures
121.05
-0.03
-0.03%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Premarket movers: Iren jumps on Anthropic deal, CCC surges on buyout talks
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
2749ea18e1· 2026-10-12 19:08 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前